Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
64 hedge funds and large institutions have $36.3M invested in Infinity Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 14 closing their positions.
859% more call options, than puts
Call options by funds: $211K | Put options by funds: $22K
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
2% more funds holding
Funds holding: 63 → 64 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
55% less capital invested
Capital invested by funds: $80.2M → $36.3M (-$43.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.95M |
| 2 |
JP Morgan Chase
New York
|
+$801K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$528K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$264K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$230K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$1.43M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.25M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$988K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$771K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$745K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$205 | -114 | -36% |
|
INFI Hedge Fund Activity: Q4 2018 in Review
64 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2018, worth a combined $36.3M — down 55% from $80.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new INFI positions and 14 closed out — a net gain of 1 holder — while 16 added to existing stakes and 14 trimmed.
The largest buyer was BVF Inc, adding an estimated $3.95M. The largest seller was Northpointe Capital, exiting entirely with an estimated $1.43M sold.
- 64 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2018, up from 63 in Q3 2018.
- Funds reported $36.3M of Infinity Pharmaceuticals, Inc. stock for Q4 2018, down 55% quarter-over-quarter.
- 15 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2018 and 14 closed out, a net change of +1 holder.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2018 was BVF Inc, an estimated $3.95M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q4 2018 was Northpointe Capital, an estimated $1.43M sold.
Based on aggregated 13F filings for Q4 2018.